Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynecologic malignancies.
暂无分享,去创建一个
John C Roeske | B. C. Penney | J. Roeske | R. Reba | A. Lujan | A. Mundt | Arno J Mundt | Bill C Penney | Anthony Lujan | Richard C Reba | S Diane Yamada | S. Diane Yamada
[1] John C Roeske,et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. , 2002, International journal of radiation oncology, biology, physics.
[2] G. Thomas. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. , 2001, Seminars in oncology.
[3] Linda Hong,et al. IMRT of large fields: whole-abdomen irradiation. , 2001, International journal of radiation oncology, biology, physics.
[4] H. Ishizaka,et al. Water fraction of lumbar vertebral bone marrow estimated from chemical shift misregistration on MR imaging: normal variations with age and sex. , 1996, AJR. American journal of roentgenology.
[5] S. Kalnicki,et al. Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms. , 2003, Gynecologic oncology.
[6] B. Maldague,et al. MR assessment of red marrow distribution and composition in the proximal femur: correlation with clinical and laboratory parameters , 1997, Skeletal Radiology.
[7] J. Roeske,et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. , 2000, International journal of radiation oncology, biology, physics.
[8] J. Roeske,et al. Intensity-modulated radiation therapy in gynecologic malignancies. , 2002, Current treatment options in oncology.
[9] Chaney,et al. Treatment Planning at the University of North Carolina at Chapel Hill. , 1992, Seminars in radiation oncology.
[10] B N Bundy,et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.
[11] D Low,et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. , 2001, International journal of radiation oncology, biology, physics.
[12] John C Roeske,et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] D. Hallahan,et al. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. , 1995, International journal of radiation oncology, biology, physics.
[14] John C Roeske,et al. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. , 2003, International journal of radiation oncology, biology, physics.
[15] S Mutic,et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. , 2001, International journal of radiation oncology, biology, physics.
[16] John C Roeske,et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. , 2001, International journal of radiation oncology, biology, physics.
[17] S. Benedict,et al. Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. , 2001, International journal of radiation oncology, biology, physics.
[18] A. Jhingran,et al. New radiation techniques in gynecological cancer , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[19] J. Roeske,et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. , 2001, Gynecologic oncology.
[20] Jun Duan,et al. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. , 2004, International journal of radiation oncology, biology, physics.
[21] C. Compton,et al. Carcinoma of the anal canal. , 2000, The New England journal of medicine.
[22] M. Thakur,et al. Radiopharmaceuticals for spleen and bone marrow studies. , 1985, Seminars in nuclear medicine.
[23] L Verhey,et al. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. , 1999, International journal of radiation oncology, biology, physics.
[24] M. van Glabbeke,et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] John C Roeske,et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. , 2002, International journal of radiation oncology, biology, physics.
[26] F. Datz,et al. The clinical use of radionuclide bone marrow imaging. , 1985, Seminars in nuclear medicine.